Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma

Neurologia Medico-Chirurgica

Volumn 53, Issue 11, 2013, Pages 779-785

  Arakawa, Yoshiki ^a   Mizowaki, Takashi ^a   Murata, Daiki ^a   Fujimoto, Koichi ^a   Kikuchi, Takayuki ^a   Kunieda, Takeharu ^a   Takahashi, Jun C ^a   Takagi, Yasushi ^a   Miyamoto, Susumu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bevacizumab; Carboplatin; Etoposide (ICE); Ifosfamide; Recurrent glioblastoma; Second recurrence

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; CARBOPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; NIMUSTINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; DACARBAZINE; INTERFERON; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONSTIPATION; DRUG TREATMENT FAILURE; FEMALE; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; LYMPHOCYTOPENIA; MALE; MEDICAL RECORD; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROTEINURIA; RADIATION DOSE; RADIOSURGERY; RETROSPECTIVE STUDY; TOXICITY TESTING; TREATMENT RESPONSE; TUMOR GROWTH; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GLIOBLASTOMA; HEMATOLOGIC DISEASES; HUMANS; IFOSFAMIDE; INTERFERONS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84888266678     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.oa2013-0211     Document Type: Article

References (25)

1. Aoki T, Mizutani T, Nojima K, Takagi T, Okumura R, Yuba Y, Ueba T, Takahashi JA, Miyatake S, Nozaki K, Taki W, Matsutani M: Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg 112: 50-56, 2010
2. Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Hilton M, Abrey L, Cloughesy T: Phase II trail of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progeression-free surveival and prelonimnary over survival results in AVAglio. Neuro-Oncol 14 (Suppl 6): 1-164, 2012
3. Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK, Lickliter JD: Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 17: 970-974, 2010
4. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009
5. Gilbert MR: RTOG 0825: Phase II double-blind placebocontrolled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 31 (Suppl; abstr 1), 2013
6. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745, 2009
7. Mrugala MM, Crew LK, Fink JR, Spence AM: Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett 4: 1082-1086, 2012
8. Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y, Sawamura Y, Matsutani M: Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 42: 887-895, 2012
9. Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28: 2051-2057, 2010
10. Perry JR, Rizek P, Cashman R, Morrison M, Morrison T: Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer 113: 2152-2157, 2008
11. Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS: Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 107: 155-164, 2012
12. Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Coan A, Threatt S, Friedman AH, Friedman HS: Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117: 5351-5358, 2011
13. Reardon DA, Herndon JE, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, Friedman HS, Vredenburgh JJ: Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer 107: 1481-1487, 2012
14. Schäfer N, Tichy J, Thanendrarajan S, Kim Y, Stuplich M, Mack F, Rieger J, Simon M, Scheffler B, Boström J, Steinbach JP, Herrlinger U, Glas M: Ifosfamide, carboplatin and etoposide in recurrent malignant glioma. Oncology 80: 330-332, 2011
15. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK: Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72: 402-407, 2012
16. Stark-Vance V: Bevacizumab and CPT-11 in the Treatment of Relapsed Malignant Glioma. Neuro-Oncol 7 (Suppl; abstr 342): 369, 2005
17. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005
18. Thompson EM, Dosa E, Kraemer DF, Neuwelt EA: Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery 67: 87-93, 2010
19. Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259, 2007
20. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007
21. Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Yoshimine T, Hashimoto N, Aoki T, Kurisu K, Natsume A, Ogura M, Yoshida J: A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol 38: 715-718, 2008
22. Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7: 335-345, 2004
23. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972, 2010
24. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P: Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256: 734-741, 2009
25. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S: Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 9: 403-407, 2011